Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ira Gantz

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 15, 2021
Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CVMatthew J Budoff, Timothy M E Davis, Alexandra G Palmer, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 15, 2015
A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitusA Brett Hauber, Kaan Tunceli, Jui-Chen Yang, et al.
Diabetes Care|August 28, 2015
Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 DiabetesWayne H-H Sheu, Ira Gantz, Menghui Chen, et al.
Current Medical Research and Opinion|April 24, 2020
Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitusJie Liu, Lisa Tarasenko, Annpey Pong, et al.
Journal of Molecular Biology|February 11, 2005
Structures of the agouti signaling proteinJoseph C McNulty, Pilgrim J Jackson, Darren A Thompson, et al.
Biochemistry|June 12, 2002
Design, pharmacology, and NMR structure of a minimized cystine knot with agouti-related protein activityPilgrim J Jackson, Joseph C McNulty, Ying-Kui Yang, et al.
Current Medical Research and Opinion|May 27, 2017
A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapyR Ravi Shankar, Silvio E Inzucchi, Victoria Scarabello, et al.
Diabetes, Obesity & Metabolism|December 5, 2019
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitusJie Liu, Shrita Patel, Nilo B Cater, et al.
Current Medical Research and Opinion|April 24, 2020
Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitusJie Liu, Lisa Tarasenko, Annpey Pong, et al.
The AAPS Journal|June 29, 2010
Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonistXiujiang Susie Li, Jace Nielsen, Brenda Cirincione, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 15, 2021
Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CVMatthew J Budoff, Timothy M E Davis, Alexandra G Palmer, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 15, 2015
A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitusA Brett Hauber, Kaan Tunceli, Jui-Chen Yang, et al.
Diabetes Care|August 28, 2015
Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 DiabetesWayne H-H Sheu, Ira Gantz, Menghui Chen, et al.
Current Medical Research and Opinion|April 24, 2020
Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitusJie Liu, Lisa Tarasenko, Annpey Pong, et al.
Journal of Molecular Biology|February 11, 2005
Structures of the agouti signaling proteinJoseph C McNulty, Pilgrim J Jackson, Darren A Thompson, et al.
Biochemistry|June 12, 2002
Design, pharmacology, and NMR structure of a minimized cystine knot with agouti-related protein activityPilgrim J Jackson, Joseph C McNulty, Ying-Kui Yang, et al.
Current Medical Research and Opinion|May 27, 2017
A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapyR Ravi Shankar, Silvio E Inzucchi, Victoria Scarabello, et al.
Diabetes, Obesity & Metabolism|December 5, 2019
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitusJie Liu, Shrita Patel, Nilo B Cater, et al.
Current Medical Research and Opinion|April 24, 2020
Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitusJie Liu, Lisa Tarasenko, Annpey Pong, et al.
The AAPS Journal|June 29, 2010
Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonistXiujiang Susie Li, Jace Nielsen, Brenda Cirincione, et al.
Pageof 7